Jim Cramer Couldn’t Stop Gushing About Johnson & Johnson (JNJ)’s Cancer Drugs

Group 1 - Johnson & Johnson (NYSE: JNJ) has seen its shares increase by 46% year-to-date and has reported significant developments in December, including FDA approval for its AKEEGA drug for prostate cancer treatment [2] - The firm announced an 83% reduction in disease risk or death for patients with relapsed/refractory multiple myeloma (RRMM) from its phase three study of TECVAYLI and DARZALEX FASPRO drugs [2] - Bank of America raised its price target for Johnson & Johnson to $220 from $204 while maintaining a Neutral rating, reflecting analyst enthusiasm for the company's cancer drug portfolio [3] Group 2 - Jim Cramer praised Johnson & Johnson for its strategic decision to spin off its orthopaedics business, indicating that the company is making the right moves by focusing on higher-margin products [3]